12:00 AM
 | 
Mar 15, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Advair salmeterol/fluticasone propionate regulatory update

Members of FDA's Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisory committees overwhelmingly voted that randomized controlled trials would best evaluate serious asthma outcomes with marketed long-acting beta-2 agonists (LABAs) when added to corticosteroids compared to corticosteroids alone to treat asthma. No official vote was taken but most of the panel...

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >